



Updates to the Medi-Cal Rx Provider Manual

February 1, 2022

The updates/additions below have been made to the *Medi-Cal Rx Provider Manual*.

For more information, see the [Medi-Cal Rx Provider Manual](#) Version 1.10 on the Medi-Cal Rx Web Portal.

Section	Update Description	Effective Date
<i>Section 3.3.3 – Remittance Advice (RA)</i>	<ul style="list-style-type: none">Added language for timing of electronic ERA release schedule.Updated upper right corner of paper remittance images to include (Checkwrite Program, Check/EFT Number, and Check/EFT Date).Updated field descriptions for newer remittance version (Checkwrite Program, Check/EFT Number, and Check/EFT Date).	February 1, 2022
<i>Section 5.0 – Medi-Cal Rx Provider Claim Appeal Processes</i>	<ul style="list-style-type: none">Updated provider guidelines for appeal submission.	February 1, 2022
<i>Section 15.1.5 – Muscle Relaxant Limitations</i>	<ul style="list-style-type: none">Section removed	February 1, 2022
<i>Section 15.6 – Cost Ceiling</i>	<ul style="list-style-type: none">Updated and made additions to the descriptions of medications exempt from the \$10,000.00 Cost Ceiling.	February 1, 2022
<i>Section 17.0 – COVID-19 Vaccine Coverage,</i>	<ul style="list-style-type: none">Added the following under For Pfizer-BioNTech COVID-19 or Pfizer Booster Dose(s): “Effective for dates of service	Varies (see Update Description to the

Section	Update Description	Effective Date
<p><i>Reimbursement, and OTC Antigen Test Kits</i></p>	<p>on or after January 3, 2022, the U.S. FDA amended the EUA for the Pfizer-BioNTech COVID-19 vaccine(s), authorizing the use of a single booster dose administration to include individuals 12 years of age and older who received their second dose of a primary vaccination series at least 5 months ago.”</p> <ul style="list-style-type: none"> • Added the following under For Moderna COVID-19 Booster Dose(s): “Effective for dates of service on or after January 7, 2022, the U.S. FDA amended the EUA for the Moderna COVID-19 vaccine to allow for administration of a booster dose to individuals 18 years of age and older who received their second dose of a primary vaccination series at least five months ago.” • Added the following verbiage: “Note: As of October 26, 2021, moderately and severely immunocompromised people aged 18 years or older... (5 months beginning January 3, 2022, for Pfizer-BioNTech vaccines, and 5 months beginning January 7, 2022 for Moderna vaccines)...” 	<p>left: "Effective for dates of service...")</p>
<p><i>Section 17.1 – Pediatric COVID-19 Vaccine Coverage</i></p>	<ul style="list-style-type: none"> • Added the following verbiage: “Effective for dates of service <i>on or after</i> January 3, 2022, the FDA amended the EUA for the use of the Pfizer-BioNTech COVID-19 vaccine for the prevention of COVID-19 to include a third primary series dose 	<p>January 3, 2022</p>

Section	Update Description	Effective Date
	<p>for children aged 5 through 11 years. Like the adult dose, children will need a third dose of the Pfizer-BioNTech COVID-19 vaccine 28 days following the second dose.”</p>	
<p><i>Section 17.3 – COVID-19 Supplemental Incentive Fee Reimbursement for In-Home Vaccine Administration</i></p>	<ul style="list-style-type: none"> • Added the following verbiage: “The reimbursement of the <i>additional</i> in-home incentive is limited to the following: <ul style="list-style-type: none"> – 4 claims in 6 months for DOS <i>on or after</i> January 3, 2022.” 	<p>January 3, 2022</p>
<p><i>Section 17.4 – Over-the-Counter (OTC) COVID-19 Antigen Test Kits (NEW!)</i></p>	<ul style="list-style-type: none"> • Added section to provide coverage policy regarding OTC COVID-19 Antigen Test Kits. • Coverage is limited to the specific test kit(s) listed in the List of Covered Emergency Use Authorization (EUA) COVID-19 Antigen Tests (this list is available on the Medi-Cal Rx Web Portal under “Forms & Information”). • Beneficiaries must be eligible on the DOS in order to receive a test or test kit • Coverage is restricted to EUA for the diagnostic condition of suspected COVID-19. • Coverage is restricted to up to 8 tests (4 kits for 2 tests/kit) per 30 days per beneficiary. • No refills are allowed; a new prescription is required for each dispensing. 	<p>February 1, 2022</p>

Section	Update Description	Effective Date
	<ul style="list-style-type: none"> • Prior authorization (PA) requests for quantities outside the allowed amounts will be denied, unless ordered or administered by a provider, following an individualized clinical assessment and with appropriate clinical justification provided. 	
<p><i>Section 17.4.1 – OTC COVID-19 Antigen Test Kits Reimbursement</i> (NEW!)</p>	<ul style="list-style-type: none"> • Added section regarding reimbursement information for OTC COVID-19 Antigen Test Kits. • Reimbursement of the covered OTC EUA U.S. FDA-authorized, self-administered COVID-19 antigen tests is based upon an established individual test Maximum Allowable Product Cost (MAPC) +23% markup. Medical supply reimbursement guidelines apply. The adjustment for the 10% provider payment reduction per Assembly Bill 97 (Chapter 3, Statutes of 2011), effective 06/01/2011, does <i>not</i> apply to these claims. 	February 1, 2022
<p><i>Section 18.4 – Medi-Cal Rx Provider Claim Inquiry Form (CIF) (DHCS 6570)</i></p>	<ul style="list-style-type: none"> • Updated provider guidelines for CIF submission and added a sample <i>Medi-Cal Rx Claim Inquiry Form (CIF)</i>. 	February 1, 2022
<p><i>Section 18.5 – Medi-Cal Rx Provider Claim Appeal Form (DHCS 6571)</i></p>	<ul style="list-style-type: none"> • Updated provider guidelines for appeal submission and added a sample <i>Medi-Cal Rx Provider Claim Appeal Form</i>. 	February 1, 2022